SecBot SecBot

BMY drug pipeline

BRISTOL MYERS SQUIBB CO · 21 rated drugs
$63.43
+1.8% 1-day · Nov 13
Next catalyst
Mar 11, 2027
Reblozyl PDUFA date · in 115 days
Typical move on FDA news
±1.8%
1-day, median of 32 events
IV rank
51
IV 31% · HV 34%
Rated drugs
21
1 bullish · 1 bearish · 1 mixed · 18 neutral
Phase 3 trials
14
1 with results posted

Upcoming catalysts

4 dated
  1. Dec 14, 2026
    BMS-986435
    Phase 2 primary completion
  2. Feb 5, 2027
    Opdivo
    Phase 2 primary completion
  3. Mar 11, 2027115d
    Reblozyl
    PDUFA date · myelofibrosis-associated anemia
  4. May 13, 2027178d
    mezigdomide
    PDUFA date · relapsed or refractory multiple myeloma

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketAt least 3-5 years away if Phase 3 trials succeed. The GOLSEEK-1 primary completion is August 2027, followed by data analysis, regulatory filing (likely 2028), and FDA review (2028-2029).

golcadomide Updated Oct 29

What to watch

The next hard catalyst is the GOLSEEK-1 Phase 3 topline readout for golcadomide + R-CHOP in high-risk large B-cell lymphoma, with primary completion estimated around August 9, 2027. A positive readout would support a future NDA filing and position golcadomide as a potential first-in-class oral CELMoD for lymphoma. A negative or mixed result would likely end the program. For BMY, a diversified mega-cap, the stock impact would be modest relative to a single-asset biotech.

Bull case
  • Golcadomide is a potential first-in-class oral CELMoD specifically designed for lymphoma with preferential lymphoid distribution, differentiating it from other CELMoDs. Phase 1/2 data showed an 89% overall response rate and 61% complete response rate in heavily pretreated relapsed/refractory follicular lymphoma patients (ASH 2025).
  • Two sibling CELMoDs from BMS (iberdomide/Zenbexus and mezigdomide/Opzykio) both received FDA accelerated approval in 2026 for multiple myeloma, validating the CELMoD platform and BMS's expertise in this drug class.
  • Golcadomide targets a large addressable market: non-Hodgkin lymphomas (DLBCL and FL) affect over 80,000 new patients annually in the US alone, and there is high unmet need for oral, chemotherapy-free options.
Bear case
  • Golcadomide is still in Phase 3 testing with no NDA filed; the GOLSEEK-1 readout is not expected until around August 2027, and Phase 3 trials in oncology frequently fail to replicate early-phase promise.
  • BMY is a mega-cap pharma ($62 stock, ~$125B market cap) with many approved blockbusters (Opdivo, Eliquis) and pipeline programs, so even a positive golcadomide readout would have limited impact on the stock price.
  • The CELMoD class carries boxed warnings for embryo-fetal toxicity and thromboembolic events (as seen with approved iberdomide), which could limit commercial uptake.
● neutral
Impact
PhaseFiled / PDUFA pending (NDA under FDA review; pivotal program completed)
Time to marketFDA decision due August 17, 2026 (~2 weeks away); if approved, commercial launch would follow later in 2026.

iberdomide Updated Aug 1

What to watch

Mark August 17, 2026 on the calendar: the FDA target action date for iberdomide in relapsed/refractory multiple myeloma. An approval would give BMY a potential first-in-class oral CELMoD (next-gen successor to its Revlimid/Pomalyst franchise) and is likely a modestly positive headline; a CRL or review extension is the bigger downside risk to watch. Because iberdomide is a small slice of a mega-cap with a rich pipeline (mezigdomide PDUFA already cited for May 2027), treat the decision as a franchise-confidence signal, not a standalone trade.

Bull case
  • FDA accepted the NDA for iberdomide + daratumumab + dexamethasone and assigned a PDUFA date of August 17, 2026, a hard, dated, near-term binary catalyst (FDA catalyst records / event ledger, stored 2026-04-30).
  • BMY's Q2 2026 earnings analysis explicitly lists iberdomide as an upcoming PDUFA catalyst (Aug 17, 2026) that 'could further derisk the long-term growth story,' alongside a strong quarter that beat EPS consensus by ~27.7% and raised full-year guidance (8-K filing analysis, filed 2026-07-30).
  • Iberdomide extends the franchise that produced Revlimid/Pomalyst, the class works, and iberdomide is positioned as the more potent next generation; the 8-K report names iberdomide and mezigdomide as the CELMoD pipeline.
Bear case
  • The same oral-myeloma class is eroding fast: Revlimid sales fell ~49% YoY and Pomalyst/Imnovid ~71% in Q2 2026 on generic competition, evidence that oral myeloma drugs face rapid pricing/competition pressure once the patent window opens (8-K filing analysis).
  • Relapsed/refractory multiple myeloma is a crowded field; iberdomide must differentiate against newer mechanisms, and no approval outcome is stored yet, so a CRL or review delay at the August 17, 2026 PDUFA is a real (if not priced) downside headline.
  • Iberdomide is a modest slice of a ~$129B company: historical BMY PDUFA/priority-review reactions in the local catalyst record were small (e.g., +3.12% and -0.74% 1-day moves; the iberdomide NDA-submission event moved BMY -1.66% 1-day), so even the binary itself has limited upside for the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (Orencia since 2005). Any Dr. Reddy's biosimilar status is unclear from available data.

abatacept Updated Oct 24

What to watch

For BMY investors, Orencia (abatacept) is a mature, slow-growth biologic facing eventual biosimilar competition; it is not a near-term binary catalyst. For RDY, any abatacept biosimilar is a small part of a large generics portfolio, watch for FDA approval/launch announcements but don't expect a major share-price move from this product alone.

Bull case
  • Orencia (abatacept) is a well-established, FDA-approved biologic with a strong safety profile across multiple indications (RA, JIA, PsA), generating steady recurring revenue for BMY.
  • Abatacept has been studied in additional indications (type 1 diabetes, graft-versus-host disease, myocarditis), which could expand its addressable market.
  • As a CTLA4-Ig fusion protein, abatacept has a unique mechanism of action that differentiates it from TNF inhibitors and JAK inhibitors in the autoimmune space.
Bear case
  • Orencia faces biosimilar competition as patents expire, which could erode BMY's market share and pricing power.
  • For Dr. Reddy's, an abatacept biosimilar would compete in a crowded autoimmune biosimilar market with pricing pressure.
  • Abatacept is a mature product with limited growth potential, BMY's Orencia sales have faced headwinds from newer RA therapies like JAK inhibitors.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and on the market (US approval March 2021; EU approval also granted).

Abecma idecabtagene vicleucel Updated Oct 29

What to watch

The next relevant event for the BCMA CAR-T competitive landscape is the FDA PDUFA date of December 23, 2026 for Gilead/Arcellx's anito-cel, which would introduce a third BCMA-directed CAR-T into the US multiple myeloma market. For BMY investors, Abecma's trajectory is more likely to be influenced by broader company dynamics (patent cliff on Eliquis/Opdivo, pipeline readouts for other assets) than by this single drug, which is an approved, mature product facing competitive erosion.

Bull case
  • Abecma is the only CAR-T with Phase 3 randomized data (KarMMa-3) showing superiority over standard regimens in triple-class-exposed relapsed/refractory multiple myeloma, with a 51% reduction in the risk of disease progression or death.
  • FDA label simplification in June 2025 (removal of REMS program and reduced monitoring requirements) removes a barrier to adoption and should support continued commercial uptake.
  • Bristol Myers fully acquired 2seventy bio in 2025, consolidating 100% of Abecma economics and manufacturing control, eliminating the prior profit-share arrangement.
Bear case
  • Abecma faces severe competitive pressure from Carvykti (J&J/Legend), which has demonstrated superior efficacy in head-to-head comparisons and is rapidly gaining market share, with Abecma sales declining ~21% in Q1 2026 vs Carvykti growing 96%.
  • A third BCMA CAR-T competitor, anito-cel (Gilead/Arcellx), has a PDUFA date of December 23, 2026, which would further fragment the addressable multiple myeloma population.
  • Within Bristol Myers' ~$50B annual revenue, Abecma's estimated ~$250M in US sales (2024 full year) is a very small contributor, making it unlikely to move the stock meaningfully as a stand-alone catalyst.
● neutral
Impact
PhasePhase 3
Time to marketRegulatory submissions for IPF have not yet been filed. If BMS submits an NDA in 2027, a potential FDA decision could come in 2028 under standard review, or sooner if Breakthrough Therapy Designation for PPF expedites the IPF review. The ALOFT-PPF readout in early 2027 will also inform the regulatory path.

admilparant Updated Oct 29

What to watch

Watch for the ALOFT-PPF topline readout in early 2027, which will determine whether admilparant can expand into the broader progressive pulmonary fibrosis market. A positive PPF result would strengthen the drug's commercial case ahead of planned regulatory submissions for IPF. Also monitor for any announced NDA submission date, which would set a PDUFA calendar.

Bull case
  • Admilparant met its Phase 3 ALOFT-IPF primary endpoint at 60 mg with a statistically significant improvement in lung function (FVC) versus placebo at 52 weeks, supporting a potential first-in-class LPA1 antagonist approval.
  • The drug showed a favorable safety and tolerability profile with low adverse-event discontinuation rates comparable to placebo in the Phase 3 trial.
  • Admilparant has FDA Breakthrough Therapy Designation for PPF and Fast Track and Orphan Drug Designations for IPF, which could expedite review.
Bear case
  • The 120 mg dose failed to show statistical significance in ALOFT-IPF, raising questions about dose response and the drug's therapeutic window. Leerink called the findings 'mixed' and downgraded BMY.
  • Liver safety concerns emerged during the program, including a patient death and a 'limited number' of liver-related events that led to a protocol amendment, though causality is unclear.
  • The IPF market already has three approved therapies (pirfenidone, nintedanib, nerandomilast), and admilparant would need to differentiate on efficacy, safety or convenience to capture share.
● neutral
Impact
PhasePhase 2 (registrational) / Phase 3 recruiting
Time to marketIf BMS submits a BLA in the coming months, a potential FDA decision could come in late 2027 or early 2028, assuming standard 6-12 month review timelines with RMAT designation benefits.

arlocabtagene autoleucel Updated Oct 29

What to watch

Watch for BMS to announce a BLA submission for arlo-cel with the FDA, likely in the coming months given the positive registrational Phase 2 results and RMAT designation. A PDUFA date would be the next hard catalyst. Also track the QUINTESSENTIAL-2 Phase 3 trial (primary completion estimated Dec 2027) for potential expansion into earlier-line therapy.

Bull case
  • The registrational Phase 2 QUINTESSENTIAL trial met its primary endpoint (overall response rate) and all key secondary endpoints, including complete response rate, in heavily pretreated patients.
  • Arlo-cel targets GPRC5D, a distinct antigen from BCMA, positioning it as a potential salvage therapy for patients who have progressed on BCMA-directed CAR-T therapies (like BMS's own Abecma or J&J's Carvykti).
  • The drug has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, which provides expedited development and review pathways.
Bear case
  • BMS did not disclose specific response-rate numbers in the September 8 press release, leaving investors to judge the magnitude of the efficacy signal without full data.
  • The drug targets a narrow population (quadruple-class exposed RRMM after prior BCMA therapy), limiting the addressable market compared to frontline or earlier-line CAR-T therapies.
  • Competition is intensifying: Gilead's anito-cel (anitocabtagene autoleucel) has a PDUFA date of Dec 23, 2026 for a similar indication, and Johnson & Johnson's BCMA-directed CAR-T therapies already dominate the space.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market in the US (November 2023 for ROS1+ NSCLC; June 2024 for NTRK+ solid tumors), EU (conditional approval January 2025), China (May 2024), and Japan (November 2025 for NTRK+).

Augtyro repotrectinib Updated Oct 29

What to watch

With no imminent PDUFA or pivotal readout, Augtyro is not a binary catalyst stock for BMY. Watch for quarterly revenue trends in BMS earnings reports to see if global launches (EU, China, Japan) move the commercial needle from its current ~$50M annual run rate. The bigger BMY story is the Growth Portfolio vs Legacy Portfolio transition, with Eliquis patent cliff approaching in 2028.

Bull case
  • Augtyro is the only FDA-approved treatment for NTRK-positive tumors studied in both TKI-naive and TKI-pretreated patients across solid tumors, giving it a differentiated label.
  • The TRIDENT-1 trial data showed compelling efficacy: high objective response rates and durable responses in both ROS1+ NSCLC and NTRK+ solid tumors, including patients previously treated with other TKIs.
  • Growing global approvals (EU, China, Japan) open additional addressable markets. China NMPA approval in May 2024 and Japan MHLW approval in November 2025 could broaden the revenue base beyond the US.
Bear case
  • BMS recorded a $1.4B impairment charge on Augtyro in Q4 2024, citing lower revised cash flow projections and an 'evolving commercial opportunity,' signaling weak commercial adoption.
  • Sales are modest at $38M in FY2024 for a drug that cost $4.1B to acquire through the Turning Point deal, implying a very poor return on investment to date.
  • The ROS1-positive NSCLC market is small (1-2% of NSCLC patients) and competitive, facing established rivals like Pfizer's Xalkori (crizotinib), Roche's Rozlytrek (entrectinib), Pfizer's Lorbrena (lorlatinib), and emerging agents like taletrectinib.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since December 2014; continuous label expansions ongoing

Opdivo nivolumab Updated Jun 30

What to watch

Opdivo is a cash-cow mega-blockbuster with steady ~$10B/year revenue, but BMY stock is driven more by the broader pipeline (iberdomide PDUFA Aug 17, 2026), the patent cliff on Eliquis and Opdivo, and the growth of newer products (Camzyos, Breyanzi, Cobenfy). Investors should watch Opdivo's quarterly sales trajectory for erosion signs as biosimilar competition approaches (US patent cliff ~2028) and track BMY's ability to offset with the subcutaneous Opdivo Qvantig launch and new indications.

Bull case
  • Opdivo generated ~$10.0B in worldwide revenue in 2025, demonstrating durable commercial scale across a dozen approved indications (source: BMS Key Facts page - bms.com).
  • The subcutaneous formulation Opdivo Qvantig (approved Dec 2024) offers a convenience advantage over IV infusion and could extend the franchise lifecycle by winning market share from IV competitors and improving patient access (source: FDA.gov - fda.gov).
  • New label expansions are still being approved, March 2026 cHL approval (+AVD chemo), April 2025 HCC approval (+Yervoy), and June 2026 EU label expansion, showing ongoing regulatory momentum (source: FDA.gov - fda.gov).
Bear case
  • Keytruda (Merck) dominates the PD-1 inhibitor market with >50% share, consistently outpacing Opdivo in new approvals and indications (source: DelveInsight - delveinsight.com).
  • Opdivo patents expire in the EU around 2026 and the US around 2028, opening the door to biosimilar competition. Amgen has already filed IPR challenges to BMS patents, and Indian biosimilar entrants like Zydus are preparing to launch (source: DrugPatentWatch - drugpatentwatch.com; Cancerworld - cancerworld.net).
  • The PD-1/PD-L1 inhibitor market is crowded with competitors including Roche's Tecentriq, AstraZeneca's Imfinzi, and Sanofi's Libtayo, all competing for the same indications (source: Synapse PatSnap - synapse.patsnap.com).
▲ bullish
Impact
PhasePhase 3 (positive interim analysis completed)
Time to marketBMS plans to discuss a regulatory submission with the FDA following the positive Phase 3 interim analysis, but no timeline has been provided. If filed, a standard FDA review would take approximately 10-12 months, suggesting a potential approval in late 2027 or 2028 at the earliest.

RYZ101 actinium (225Ac) oxodotreotide Updated Oct 29

What to watch

The next catalyst is BMS's engagement with the FDA to discuss a regulatory submission for RYZ101 in GEP-NETs, following the positive Phase 3 ACTION-1 interim analysis announced October 12, 2026. No PDUFA date has been set. Detailed efficacy and safety data from ACTION-1 are expected at a future medical meeting, which could provide further clarity on the magnitude of the PFS benefit. For a diversified mega-cap like BMY, RYZ101 is a pipeline positive but not a stock-moving binary event.

Bull case
  • RYZ101 is the first alpha-emitting radiopharmaceutical to succeed in a Phase 3 trial, a potential first-in-class and first-in-category milestone.
  • The ACTION-1 trial met its primary endpoint (PFS) with statistical significance in a high-need population: GEP-NET patients who progressed after lutetium-177 therapy, where no randomized Phase 3 data previously existed.
  • FDA granted Orphan Drug Designation for GEP-NETs in August 2026, which provides market exclusivity and development incentives.
Bear case
  • Detailed efficacy numbers (hazard ratio, median PFS) from ACTION-1 have not been disclosed, making it impossible to assess the magnitude of benefit versus standard of care.
  • RYZ101 is a small part of BMY's massive pipeline ($13B+ quarterly revenue). Even a successful approval would have limited impact on BMY's share price.
  • Manufacturing and supply-chain challenges for actinium-225 radiopharmaceuticals are significant; BMS is investing $170M+ in a new facility, but scaling remains unproven.
● neutral
Impact
PhaseApproved; post-market Phase 3 long-term safety extension completed
Time to marketAlready approved and on the market — FDA approval recorded April 28, 2022 (per local FDA catalyst records)

Camzyos mavacamten Updated Aug 2

What to watch

Watch for two things: (1) BMY posting MAVA-LTE long-term safety data for Camzyos (safety of the myosin-inhibitor class is the key risk) and quarterly Growth Portfolio/Camzyos sales commentary; and (2) the bigger HCM binary this year is actually the competitor's, Cytokinetics' aficamten (MYQORZO) has a PDUFA on 2026-11-14, which will set the competitive narrative for Camzyos. Do not expect a Camzyos-specific binary to move BMY much on its own.

Bull case
  • Already approved (FDA approval recorded 2022-04-28) and commercialized, the defining regulatory binary has passed, removing approval risk for the obstructive-HCM indication.
  • Fits within a strong company backdrop: BMY's Q2 2026 earnings 8-K (per local LLM analysis) beat consensus, non-GAAP EPS of $2.04 vs $1.60 estimate and revenue of $13.0B vs $11.74B, and FY2026 revenue guidance was raised to $49.0B-$50.0B, with Camzyos part of the Growth Portfolio.
  • BMY screens inexpensive on local quant data (forward P/E 9.88, quant composite score 45) and short interest is modest (2.20% of estimated shares outstanding, 4.24 days-to-cover at the 2026-07-15 settlement), leaving room for a positive surprise.
Bear case
  • Direct competition is ahead on data: Cytokinetics' aficamten (MYQORZO) is already approved for obstructive HCM in the US, EU and China (per local press records), posted positive Phase 3 ACACIA-HCM results in non-obstructive HCM on 2026-05-05 (dual primary endpoints met), and has a PDUFA of 2026-11-14 for the MAPLE-HCM oHCM expansion, a faster-moving franchise that could pressure Camzyos' share.
  • No near-term hard catalyst for Camzyos itself: the long-term safety extension completed 2026-01-16 but results are not posted and no readout date is set; safety of the myosin-inhibitor class (heart-failure risk) is the ongoing watch item.
  • Camzyos is a small piece of a mega-cap, so single-drug news moves BMY little, the stock was actually DOWN -0.71% (1-day) around the 2022-04-28 approval date per local catalyst-outcome records.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2015. No new regulatory filing or label expansion is imminent based on available information.

Empliciti elotuzumab Updated Oct 29

What to watch

Empliciti has no near-term binary catalysts. The next meaningful event to watch is the 2029-2030 patent expiry window, which could open the door to biosimilar competition, but that is several years away. For BMY investors, Empliciti is a non-factor; attention should be on the company's growth portfolio (Reblozyl, Breyanzi, Camzyos, Cobenfy) and the upcoming Eliquis patent cliff.

Bull case
  • Empliciti remains a commercially viable option in the multiple myeloma treatment landscape with established combination regimens (ERd and EPd) and ongoing use in clinical practice.
  • The global elotuzumab market is projected to grow at a CAGR of roughly 7-8% through 2034, driven by rising multiple myeloma prevalence and demand for targeted cancer therapies.
  • Key US composition-of-matter patent protection extends to 2029-2030, providing a continued exclusivity runway with no near-term biosimilar threat.
Bear case
  • Empliciti faces intense competition from far larger multiple myeloma therapies, particularly Johnson & Johnson's daratumumab (Darzalex, ~$6B+ in annual sales), which has broader label indications and subcutaneous formulation advantages.
  • Annual sales of roughly $80-100 million are immaterial to BMY's ~$48B+ total revenue, meaning the drug has essentially no impact on the company's financial performance or stock valuation.
  • A Phase 3 trial (ELOQUENT-1) failed to show benefit in newly diagnosed multiple myeloma, limiting label expansion potential, and the drug's use is confined to later-line relapsed/refractory settings.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval August 16, 2019; European Commission approval February 2021).

Inrebic fedratinib Updated Oct 29

What to watch

Inrebic is an already-approved, marketed drug with no upcoming PDUFA or pivotal readout. The next potential catalyst to watch is whether BMS pursues a label expansion into MDS/MPN overlap syndromes based on the Phase 2 data presented at ASCO 2026, but no sNDA filing has been announced. For a company the size of BMY ($48B+ annual revenue), Inrebic is a minor product whose sales are not even broken out separately, so even a label expansion would be a modest contributor.

Bull case
  • Inrebic was the first new FDA-approved treatment for myelofibrosis in nearly a decade (approved August 2019), offering a differentiated oral JAK2-selective option for patients who are intolerant of or progress on ruxolitinib.
  • Phase 2 data presented at ASCO 2026 showed fedratinib produced clinical benefit in MDS/MPN overlap syndromes and chronic neutrophilic leukemia, suggesting potential for label expansion into additional rare blood cancer indications.
  • Patent protection extends to approximately 2039, providing a long runway of market exclusivity with no near-term generic threat.
Bear case
  • Inrebic is a minor product for BMY: the company does not break out its revenue separately in SEC filings, signaling it is immaterial to the overall $48B+ annual revenue base.
  • The myelofibrosis market is dominated by Incyte's Jakafi (ruxolitinib), which has a strong first-mover advantage and multiple approved indications. Inrebic also faces competition from newer JAK inhibitors like pacritinib and momelotinib.
  • Inrebic carries a boxed warning for serious gastrointestinal toxicity, including diarrhea, nausea and vomiting, which can limit its tolerability and adoption.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2011.

Nulojix belatacept Updated Oct 29

What to watch

Nulojix has no scheduled PDUFA dates, AdComms, or pivotal readouts in the next 12 months. Watch for any label expansion into pediatric kidney transplant or heart transplant (Phase 2 data ongoing), but neither represents a near-term binary event. The main long-term risk is biosimilar entry as patents expire, with Alphamab Oncology's KN019 (belatacept biosimilar) in Chinese clinical development.

Bull case
  • Nulojix offers a kidney-sparing alternative to calcineurin inhibitors, a meaningful clinical advantage that supports steady adoption at transplant centers.
  • No approved biosimilar exists as of 2026, providing continued market exclusivity for BMS.
  • Published pediatric data and an ongoing Phase 2 heart transplant trial suggest potential for future label expansion into broader transplant populations.
Bear case
  • Nulojix is a niche product with un-disclosed revenue buried in BMS's 'Other Growth Brands' category, meaning it has negligible impact on BMY's overall financials.
  • The drug carries a boxed warning for post-transplant lymphoproliferative disorder (PTLD) and is contraindicated in EBV-seronegative patients, limiting its addressable market.
  • Biosimilar competition is emerging (Alphamab's KN019 in China), and eventual patent expiration will erode what modest revenue the drug generates.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. (since September 2020) and EU (since June 2021).

Onureg azacitidine Updated Oct 29

What to watch

Onureg is already approved and marketed with no pending regulatory decision. The next catalysts to watch are data readouts from ongoing early-stage combination trials (CC-486 with venetoclax in AML/MDS), but these are Phase 1/1b and Phase 1/2 studies, not pivotal registrational trials. For a diversified giant like BMS, Onureg is a minor product grouped under "Other Growth Brands" and is unlikely to drive material share-price movement on its own.

Bull case
  • Onureg is the first and only FDA-approved oral maintenance therapy for AML patients in first remission, offering a convenient at-home alternative to injectable azacitidine.
  • The pivotal QUAZAR AML-001 trial showed a clinically meaningful nearly 10-month overall survival benefit (24.7 vs 14.8 months) versus placebo, providing strong efficacy data.
  • EMA approval in Europe (June 2021) and ongoing combination trials with venetoclax could expand the addressable market into earlier lines and MDS.
Bear case
  • Onureg is a minor product for BMS, grouped under 'Other Growth Brands' with no individually reported revenue, meaning even strong sales growth has negligible impact on a ~$50B revenue company.
  • Generic injectable azacitidine already exists, and Dr. Reddy's launched a generic version in the U.S. in 2024, pressuring pricing. Oral azacitidine patents begin expiring around 2029-2030, with generic entry estimated around June 2030.
  • The addressable patient population is narrow: only older AML patients in first remission who cannot undergo stem cell transplant, limiting peak revenue potential.
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and marketed — initial US approval was 2005; no approval timeline applies. Remaining question is how fast generic share grows after volume caps ended Jan 31, 2026.

Revlimid lenalidomide Updated Aug 2

What to watch

For BMY shareholders, Revlimid is no longer a stock-moving binary, Q2 2026 sales fell ~49% YoY on generic erosion and full-year guidance was raised anyway, so the thesis now lives in the Growth Portfolio. Watch the quarterly earnings prints for the pace of post-volume-cap erosion, and note that the actual multiple-myeloma franchise catalysts are BMS's separate drugs iberdomide (PDUFA Aug 17, 2026) and mezigdomide (PDUFA May 13, 2027), not Revlimid.

Bull case
  • Demand base is durable: Revlimid remains a standard backbone in newly diagnosed multiple myeloma and del 5q MDS (revlimid.com, revlimidhcp.com), and the brand is protected operationally by the Lenalidomide REMS restricted-distribution program.
  • BMS managed the cliff better than typical: patent settlements (e.g., 2020 Dr. Reddy's deal) staggered generic entry, and the decline from $12.8B (2021) to ~$6B (2023) was gradual, not a 90% overnight collapse (globalpricing.com, briefglance).
  • The erosion is largely 'in the numbers': despite Revlimid falling ~49% YoY in Q2 2026, BMS beat consensus and RAISED full-year 2026 guidance, so there is little remaining downside surprise left in this asset for BMY (8-K analysis).
Bear case
  • Revenue is in freefall: from $12.8B in 2021 to $6B in 2023, and down ~49% YoY in Q2 2026 per BMS's own earnings materials (briefglance; 8-K analysis).
  • The generics floodgates are now fully open: volume restrictions under patent settlements ended Jan 31, 2026, and multiple players (Accord, Dr. Reddy's, Alvogen, Apotex, Cipla) are competing on price (ASHP, Reuters, business-standard).
  • No upside catalyst exists for this drug, no PDUFA, no pivotal readout, no label-expansion decision is scheduled; it is a one-way declining asset whose only 'news' is how fast it shrinks.
● neutral
Impact
PhaseApproved (US approval recorded 2020-03-25); no active Phase 2/3 industry-sponsored trials for ozanimod/Zeposia in SecBot
Time to marketAlready on the market — approved (US FDA approval recorded 2020-03-25 in SecBot's local catalyst data); commercialized by Bristol Myers Squibb.

Zeposia ozanimod Updated Aug 2

What to watch

There is no near-term Zeposia-specific event to trade, the drug's binary (approval) already passed in 2020, and BMY's scheduled FDA catalysts in local data are other assets (iberdomide PDUFA 2026-08-17; Reblozyl PDUFA 2027-03-11; mezigdomide PDUFA 2027-05-13). Watch BMY's quarterly filings (10-Q/8-K) for the Zeposia sales line if you want to track this product specifically; the stock is more likely to move on BMY's portfolio-wide results and those other catalysts than on Zeposia alone.

Bull case
  • Zeposia is already FDA-approved and commercialized, so it contributes revenue with no regulatory-approval risk remaining.
  • The market reacted positively to Zeposia milestones historically: the recorded approval catalyst coincided with a +6.11% 1-day and +10.46% 5-day move in BMY (local outcomes record).
  • Zeposia is a named product in BMY's portfolio per the Q2 2026 earnings 8-K analysis, and BMY as a whole is in a strong operating stretch, non-GAAP EPS of $2.04 beat the $1.60 consensus by ~27.7% and full-year revenue guidance was raised to $49.0B-$50.0B (local filing analysis).
Bear case
  • No Zeposia-specific catalyst is scheduled in local FDA/event data for the next ~12 months, the approval binary already passed, so there is no dated event for the stock to trade on.
  • Zeposia is a small part of BMY's portfolio; BMY's near-term FDA catalysts in local data are other drugs (iberdomide PDUFA 2026-08-17, Reblozyl PDUFA 2027-03-11, mezigdomide PDUFA 2027-05-13), and the Q2 2026 analysis credits growth to Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag, not Zeposia.
  • Analyst positioning is lukewarm: consensus recommendation is 'hold' (8 buy, 6 strong buy, 19 hold, 2 sell) with a mean price target of $64.91 vs. a $65.31 share price, roughly flat implied upside (local analyst data).
◆ mixed
Impact
PhasePhase 1 (with Phase 3 initiated but suspended)
Time to marketAt least 4-6 years away, if successful. The program is in early Phase 1 for MS and other autoimmune indications, with a Phase 3 systemic sclerosis trial that is currently suspended. Even after enrollment resumes, pivotal data collection and regulatory review would take several years.

zolacabtagene autoleucel Updated Oct 29

What to watch

The next catalyst is BMS's discussions with the FDA to restart zola-cel autoimmune trial enrollment, targeted for early 2027. A successful restart would signal that safety concerns are addressable and could de-risk the broader autoimmune CAR T thesis, while further delays or additional safety signals would deepen the overhang. Given BMY's diversified revenue base, even a complete program setback would have limited stock impact, but positive regulatory resolution could provide modest upside for the cell therapy pipeline narrative.

Bull case
  • All 60 patients at the therapeutic dose level in Breakfree-2 remained off disease-modifying therapies, including 9 patients with over 12 months of follow-up, suggesting durable efficacy from a single infusion.
  • The NEX-T rapid manufacturing platform (~2 day production) could give zola-cel a competitive advantage over slower CAR T manufacturing processes if approved.
  • EU orphan drug designation for systemic sclerosis provides regulatory support and market exclusivity incentives in a serious disease with high unmet need.
Bear case
  • A patient died of septic pneumonia 44 days after zola-cel infusion, and BMS voluntarily paused all autoimmune trial enrollment in August 2026 due to inflammatory safety events, creating significant regulatory uncertainty.
  • The Phase 3 Breakfree-SSc trial in systemic sclerosis is currently suspended, and the timeline for restarting enrollment (targeted early 2027) is not guaranteed.
  • Novartis halted all 8 autoimmune trials of its competing CD19 CAR T (rap-cel) after 3 patient deaths, raising class-wide safety concerns for CD19 CAR T therapy in autoimmune diseases.
● neutral
Impact
PhaseApproved / marketed (legacy product)
Time to marketAlready on the market — a long-approved, marketed chemotherapy (US sales began in the mid-2000s); no further approval needed.

Abraxane nab-paclitaxel Updated Aug 2

What to watch

Do not trade BMY on Abraxane, it is a declining, generics-exposed legacy chemotherapy with no scheduled catalyst and immaterial weight in a ~$129B company. If you hold BMY, the stock thesis is driven by the Growth Portfolio (Opdivo, Eliquis, Breyanzi) and pipeline PDUFAs, not this drug; track Abraxane only as a line item within Legacy Portfolio erosion at quarterly earnings.

Bull case
  • Fully de-risked and cash-generating: the drug is already approved and marketed, and its owner BMY is financially strong, Q2 2026 revenue of $12.973B beat consensus by 10.5% and full-year guidance was raised (per BMY 8-K filing analysis).
  • Still a clinically relevant backbone: local trial and event records show nab-paclitaxel remains a standard chemotherapy partner in pancreatic cancer (gemcitabine/Abraxane), TNBC, and NSCLC combination studies, indicating ongoing real-world demand.
  • The albumin-bound nanoparticle formulation is a genuine differentiator vs. solvent-based paclitaxel (Taxol), the historical rationale for its use.
Bear case
  • Mature, declining legacy asset: BMY's Legacy Portfolio revenue fell 4% YoY in Q2 2026, with the company's filing analysis citing generic erosion on legacy drugs (Revlimid -49%, Pomalyst/Imnovid -71%, Sprycel -27%), Abraxane is not called out as a growth driver.
  • No catalysts: local data shows zero FDA actions, catalysts, or price-reaction outcomes for Abraxane in the past year-plus, and no BMS-sponsored late-stage trials for it, the drug's defining regulatory binary passed years ago.
  • Immaterial to the stock: BMY trades at ~$65.31 with a market cap near $129B and a consensus 'hold' (mean price target $64.91 vs. current price, implying roughly -0.5% upside), so Abraxane-specific events would barely move the shares.
● neutral
Impact
PhaseApproved / marketed (originally approved Feb 2013); still used as the comparator/backbone arm in other sponsors' Phase 3
Time to marketAlready marketed — FDA approval catalyst recorded 2013-02-08; generic pomalidomide (Camber Pharmaceuticals, ANDA210236) already has U.S. labeling, so the brand's exclusivity is gone.

Pomalyst/Imnovid pomalidomide Updated Aug 2

What to watch

Do not trade BMY on Pomalyst, there is no pending approval, readout, or label decision for this drug. Watch BMS quarterly filings (latest 10-Q filed 2026-07-30) for Pomalyst/Imnovid sales erosion vs. generics, and note that the real near-term myeloma catalyst for the ticker is a DIFFERENT molecule: BMY's next-gen IMiD iberdomide has a PDUFA of 2026-08-17 per SecBot event data. An AbbVie Phase 3 (venetoclax vs. pomalidomide+dex, NCT03539744) has an estimated primary completion of August 2026 and uses Pomalyst as the comparator arm.

Bull case
  • Approved, on-market franchise with a long track record: SecBot records an FDA approval catalyst for POMALYST on 2013-02-08 (stock +1.48% on the 1-day move around it).
  • Still a standard-of-care backbone in later-line myeloma: pomalidomide+dexamethasone is the comparator arm in BMS/Celgene Phase 3 NCT03651128 (386 enrolled, completed 2026-04-13) and in AbbVie's Phase 3 NCT03539744 (265 enrolled), it remains a reference therapy in the class.
  • The IMiD class stays strategically relevant to BMS: the next-generation successor iberdomide has a PDUFA of 2026-08-17, so BMS retains a franchise around this drug family.
Bear case
  • Generic erosion is real: FDA action data shows generic pomalidomide (Camber Pharmaceuticals, ANDA210236) with safety labeling effective 2026-03-04, meaning U.S. brand exclusivity for Pomalyst is gone and revenue is being competed away.
  • Mature late-line niche under competitive pressure: pomalidomide is used after ≥2 prior therapies and faces newer options (CAR-T such as BMS's own bb2121, bispecifics, daratumumab-based combos) that are squeezing the same patient pool.
  • No catalyst and immaterial to the stock: there is no PDUFA, pivotal readout, or label decision scheduled for Pomalyst itself, and it is a minor revenue line within BMS, BMY's quant/technical profile (RSI 71.4, +48.9% over 12 months) is driven by other factors, not this drug.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market — FDA approved June 28, 2006; now in the generic-erosion phase of its life cycle.

Sprycel dasatinib Updated Aug 2

What to watch

Do not trade BMY on Sprycel news, the binary (approval) passed 20 years ago and its erosion is immaterial to a ~$129B market-cap company whose stock is driven by the Growth Portfolio (Opdivo, Reblozyl, Eliquis, etc.). Track it only as a line in BMY's Legacy Portfolio in quarterly filings; BMY's real near-term FDA catalysts are other drugs: iberdomide PDUFA August 17, 2026, Reblozyl March 11, 2027, and mezigdomide May 13, 2027.

Bull case
  • Established standard-of-care: FDA approval recorded June 28, 2006 for BMY, giving it a ~20-year commercial track record in CML and Ph+ ALL.
  • Still a marketed Legacy Portfolio product with franchise revenue; BMY's Q2 2026 8-K materials show the Legacy Portfolio generated $5.4B in the quarter (with Eliquis up 22% offsetting generic erosion elsewhere).
  • For a ~$129B market-cap BMY with analyst consensus 'hold' and mean price target $64.91 vs. ~$65.31 price, Sprycel's decline is immaterial to the stock, which is driven by the growing Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag).
Bear case
  • Generic erosion is real and accelerating: BMY's Q2 2026 earnings materials report Sprycel revenue down 27% YoY, the fastest-declining named legacy drug alongside Revlimid (-49%) and Pomalyst/Imnovid (-71%).
  • No growth catalysts: the drug's defining binary (FDA approval) passed in 2006, and no BMS-sponsored pivotal dasatinib trials are in SecBot's clinical-trial feed, only investigator-initiated studies, so there is no label-expansion or data readout to re-rate the asset.
  • Competitive TKI field: dasatinib competes with multiple other marketed BCR-ABL inhibitors and now low-cost generics, pressuring volume and price in a small leukemia market (generic competition confirmed in BMY's 8-K analysis).

Other drugs in filings and trials

no drug report yet
  • Reblozyl Next: PDUFA date · Mar 11, 2027 Last: BLA filed · Jul 30, 2026
  • mezigdomide Next: PDUFA date · May 13, 2027 Last: NDA filed · Jul 13, 2026
  • Sotyktu Last: PDUFA decision · Mar 6, 2026
  • ELIQUIS Last: Approval · Apr 17, 2025
  • KRAZATI Last: Approval · Dec 12, 2022
  • IDHIFA Last: Approval · Aug 1, 2017
  • DAKLINZA Last: Approval · Jul 24, 2015
  • EVOTAZ Last: Approval · Jan 29, 2015
  • OTEZLA Last: Approval · Sep 23, 2014
  • REYATAZ Last: Approval · Jun 2, 2014
  • Adagrasib 1 trial
  • BMS-986165 1 trial
  • BMS-986435 1 trial
  • HBI-8000 in combination with nivolumab 1 trial
  • Ipilimumab 1 trial
  • Ipilimumab/ Nivolumab 1 trial
  • N-acetyl cysteine 1 trial
  • probenecid 1 trial
  • Xanomeline and Trospium Chloride Capsules 1 trial

Past FDA events & how the stock moved

32 events
DateDrugEvent1 day5 days
Aug 17, 2026iberdomideNDA filed+3.5%+5.4%
Aug 17, 2026iberdomidePDUFA decision+3.5%+5.4%
Jul 30, 2026ReblozylBLA filed+3.5%+1.7%
Jul 13, 2026mezigdomideNDA filed−1.1%+4.5%
Apr 8, 2026OpdivoPriority review+3.1%+0.4%
Apr 8, 2026OpdivoPDUFA decision+3.1%+0.4%
Mar 6, 2026SotyktuPDUFA decision−0.2%−2.7%
Feb 17, 2026iberdomideNDA filed−1.7%+1.4%
Dec 11, 2025OpdivoPriority review+2.3%+4.1%
Jul 13, 2025mezigdomideNDA filed+1.0%+1.1%
Apr 17, 2025ELIQUISApproval−0.8%−3.0%
Mar 11, 2025ReblozylBLA filed−5.2%−5.1%
Mar 6, 2025SotyktuPDUFA decision+2.1%+0.8%
Dec 27, 2024OpdivoApproval−3.3%−1.2%
Nov 15, 2023AugtyroApproval+0.6%−2.2%
Dec 12, 2022KRAZATIApproval−1.9%−7.2%
Sep 9, 2022SOTYKTUApproval+4.3%+3.1%
Apr 28, 2022CamzyosApproval−0.7%+0.6%
Mar 18, 2022OpdualagApproval+0.8%+3.9%
Sep 1, 2020OnuregApproval−1.0%−5.0%
Mar 25, 2020ZeposiaApproval+6.1%+11.3%
Nov 8, 2019REBLOZYLApproval+1.0%+1.8%
Aug 1, 2017IDHIFAApproval−2.9%+0.0%
Nov 30, 2015EmplicitiApproval+0.6%+1.5%
Jul 24, 2015DAKLINZAApproval−5.8%−3.8%
Mar 4, 2015OpdivoApproval+6.7%+5.9%
Jan 29, 2015EVOTAZApproval−1.7%−1.8%
Dec 22, 2014OpdivoApproval−3.5%−2.5%
Sep 23, 2014OTEZLAApproval+0.6%−0.9%
Jun 2, 2014REYATAZApproval−1.5%−6.3%
Feb 8, 2013Pomalyst/ImnovidApproval+1.2%+0.3%
Dec 28, 2012ELIQUISApproval+1.4%+5.0%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
OpdivoA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Phase 2Active not recruiting76Feb 5, 2027
BMS-986435Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Phase 2Active not recruiting227Dec 14, 2026
phenoxymethyl penicillinGOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD TrialPhase 2Completed1,004Oct 31, 2026
RevlimidNivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaPhase 2Completed36Aug 28, 2026
SprycelImproving Physical Ability and Cellular Senescence Elimination in HIVPhase 2Completed82Aug 26, 2026
OpdivoImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyPhase 2Terminated5Aug 13, 2026
AdagrasibTrial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Phase 2Active not recruiting200Jul 30, 2026
BMS-986165Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisPhase 3Completed1,466Jul 21, 2026
MezigdomideA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Phase 3Active not recruiting606Jul 18, 2026
OpdivoA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaPhase 3Completed732Jul 9, 2026
HBI-8000 in combination with nivolumabStudy Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaPhase 3Active not recruiting450Jul 2026
OpdivoCombination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation TherapyPhase 2Completed44Jun 19, 2026
OpdivoTemozolomide, Cisplatin, and Nivolumab in People With Colorectal CancerPhase 2Completed18Jun 17, 2026
NulojixAbatacept Conversion in Kidney TransplantationPhase 2Completed87Jun 10, 2026
OpdivoNivolumab and Ipilimumab in People With Aggressive Pituitary TumorsPhase 2Completed10Jun 1, 2026
InrebicA Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Phase 2Active not recruiting216May 31, 2026
OpdivoA Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid TumorsPhase 2Active not recruiting150May 30, 2026
OpdivoPET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin LymphomaPhase 2Completed37May 1, 2026
OnuregRandomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCTPhase 3Completed326Apr 29, 2026
SprycelSenolytics to Improve Osteoporosis TherapyPhase 2Completed120Apr 24, 2026
Ipilimumab/ NivolumabSBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerPhase 2Completed66Apr 23, 2026
AbecmaEfficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Phase 3Completed386Apr 13, 2026
NulojixDaratumumab and Belatacept for DesensitizationPhase 2Completed19Apr 2, 2026
Xanomeline and Trospium Chloride CapsulesAn Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPhase 3Completed290Mar 25, 2026
OpdivoSafety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaPhase 2Completed · results33Mar 12, 2026
OpdivoSitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerPhase 2Terminated15Mar 11, 2026
IpilimumabNeoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerPhase 2Terminated1Mar 9, 2026
N-acetyl cysteineProspective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) TrialPhase 3Completed202Mar 2, 2026
SprycelDasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver DiseasePhase 2Completed30Feb 26, 2026
EmplicitiContinuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabPhase 2Completed67Feb 23, 2026
OpdivoA Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerPhase 3Completed855Feb 16, 2026
OpdivoA Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabPhase 2Terminated15Feb 1, 2026
RevlimidLenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaPhase 3Completed514Jan 30, 2026
JPB898 (Induction and Maintenance)Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®Phase 3Terminated52Jan 23, 2026
OpdivoStudy to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaPhase 3Completed343Jan 20, 2026
CamzyosA Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMPhase 3Completed314Jan 16, 2026
AbecmaAn Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaPhase 2Completed312Jan 15, 2026
probenecidThe Re-Prosper HF StudyPhase 3Completed · results125Dec 31, 2025
OpdivoNivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryPhase 2Completed · results26Dec 15, 2025
OpdivoStudy of DF1001 in Patients With Advanced Solid TumorsPhase 2Completed270Dec 5, 2025